Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Christians

Showing results (81-90 of 86) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 86 results.
European Journal of Clinical Pharmacology|January 1, 1991
Ciclosporin metabolite pattern in blood and urine of liver graft recipients. I. Association of ciclosporin metabolites with nephrotoxicityU Christians, K Kohlhaw, J Budniak, et al.
Therapeutic Drug Monitoring|January 8, 1998
Pitfalls in monitoring tacrolimus (FK 506)F Braun, E Schütz, U Christians, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|December 9, 2000
Efficacies of sirolimus (rapamycin) and cyclosporine in allograft vascular disease in non-human primates: trough levels of sirolimus correlate with inhibition of progression of arterial intimal thickeningT S Ikonen, J F Gummert, N Serkova, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 1, 1995
Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variabilityA Lampen, U Christians, F P Guengerich, et al.
Transplantation|March 9, 2000
Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycinB Hausen, J Gummert, G J Berry, et al.
Transplantation|February 1, 2000
Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerabilityB Hausen, T Ikonen, N Briffa, et al.
Pageof 9

Showing results (81-90 of 86) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 86 results.
European Journal of Clinical Pharmacology|January 1, 1991
Ciclosporin metabolite pattern in blood and urine of liver graft recipients. I. Association of ciclosporin metabolites with nephrotoxicityU Christians, K Kohlhaw, J Budniak, et al.
Therapeutic Drug Monitoring|January 8, 1998
Pitfalls in monitoring tacrolimus (FK 506)F Braun, E Schütz, U Christians, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|December 9, 2000
Efficacies of sirolimus (rapamycin) and cyclosporine in allograft vascular disease in non-human primates: trough levels of sirolimus correlate with inhibition of progression of arterial intimal thickeningT S Ikonen, J F Gummert, N Serkova, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 1, 1995
Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variabilityA Lampen, U Christians, F P Guengerich, et al.
Transplantation|March 9, 2000
Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycinB Hausen, J Gummert, G J Berry, et al.
Transplantation|February 1, 2000
Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerabilityB Hausen, T Ikonen, N Briffa, et al.
Pageof 9